title: [Neutralizing antibodies in hepatitis C virus infection].
abstract: Hepatitis C virus (HCV) results in persistent infection in more than 70% of infected individuals despite the development of humoral and cellular immune responses. Following infection, although antibodies targeting epitopes of both structural and non structural proteins are elicited, the virus evades antibody-mediated neutralization. Studies of host neutralizing responses against HCV have been limited by the lack of a convenient tissue culture system for HCV infection. In the past five years in vitro models have been developed to characterize interaction of HCV glycoproteins with host cell entry factors and detect antibodies interfering with HCV entry and infection. These models have been used to characterize targets of neutralizing responses and better understand their impact on the pathogenesis of infection.
authors.affiliation: Laboratoire de virologie, Inserm U748, 3, rue Koeberlé, 67000 Strasbourg, France.
authors.forename: S
authors.initials: S
authors.lastname: Fafi-Kremer
authors.forename: M B
authors.initials: MB
authors.lastname: Zeisel
authors.forename: E
authors.initials: E
authors.lastname: Schvoerer
authors.forename: E
authors.initials: E
authors.lastname: Soulier
authors.forename: F
authors.initials: F
authors.lastname: Habersetzer
authors.forename: P
authors.initials: P
authors.lastname: Wolf
authors.forename: M
authors.initials: M
authors.lastname: Doffoel
authors.forename: T F
authors.initials: TF
authors.lastname: Baumert
authors.forename: F
authors.initials: F
authors.lastname: Stoll-Keller
mesh_terms: D000818:Animals; D016174:Hepacivirus / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy*; D018937:Hepatitis C Antibodies / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods
chemical_list: D018937:Hepatitis C Antibodies